Guerbet Logo

Guerbet

Develops contrast media and medical devices for diagnostic and interventional imaging.

GBT | PA

Overview

Corporate Details

ISIN(s):
FR0000032526 (+3 more)
LEI:
969500WV1U1WQ059L135
Country:
France
Address:
15 RUE DES VANESSES, 93420 VILLEPINTE

Description

Guerbet is a global specialist in medical imaging, offering a comprehensive range of solutions and services for diagnostic and interventional procedures. The company develops and manufactures contrast media, medical devices such as injectors, and related software for X-ray, Magnetic Resonance Imaging (MRI), and Interventional Imaging. With a history of innovation dating back to 1926, Guerbet focuses on providing healthcare professionals with tools to enhance diagnostic accuracy and improve patient care. Its portfolio is designed to support a wide array of clinical applications, from initial diagnosis to treatment monitoring.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-02 17:45
GUERBET : Ajustement des objectifs financiers 2025.
French 157.0 KB
2025-12-02 17:45
GUERBET : Adjustment of 2025 financial targets.
English 150.5 KB
2025-11-24 17:44
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 153.1 KB
2025-11-19 13:47
GUERBET : Calendrier financier de l’exercice 2026
French 198.7 KB
2025-11-19 13:47
GUERBET : Financial agenda for 2026
English 172.2 KB
2025-10-23 17:45
Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3…
French 294.9 KB
2025-10-23 17:45
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmat…
English 305.6 KB
2025-10-14 17:30
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 158.6 KB
2025-09-24 17:45
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on…
English 524.6 KB
2025-09-24 17:45
Guerbet : Résultats semestriels 2025 : Chiffre d’affaires du 1er semestre : 387…
French 496.3 KB
2025-09-22 17:45
Guerbet : Evolution de la Direction Générale
French 134.4 KB
2025-09-22 17:45
Guerbet : Change in General Management
English 113.8 KB
2025-09-18 17:45
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 159.1 KB
2025-09-15 17:50
Guerbet : Ajustement des objectifs financiers annuels 2025
French 209.3 KB
2025-09-15 17:50
Guerbet : Adjustment of 2025 full-year financial targets
English 186.1 KB

Automate Your Workflow. Get a real-time feed of all Guerbet filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Guerbet

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Guerbet via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-19 N/A Other Buy 142 4,989.31 EUR
2024-08-15 N/A Other Buy 195 6,678.75 EUR
2024-08-12 N/A Other Buy 1,000 34,350.00 EUR
2024-04-18 N/A Other Sell 550 17,699.00 EUR
2023-11-30 N/A Other Sell 700 12,684.00 EUR
2023-11-03 N/A Other Buy 1 17.92 EUR
2023-10-30 N/A Other Buy 1,000 17,000.00 EUR
2023-10-25 N/A Other Buy 1,000 16,800.00 EUR
2023-10-24 N/A Other Buy 1,000 16,460.90 EUR
2023-05-04 N/A Other Buy 300 4,938.00 EUR

Peer Companies

ABEONA THERAPEUTICS INC. Logo
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
United States of America
ABEO
ABINGDON HEALTH PLC Logo
A CDMO specializing in lateral flow assays, offering development to manufacturing services.
United Kingdom
ABDX
ABIONYX Pharma Logo
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
France
ABNX
ABIVAX Logo
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
France
ABVX
Abivax S.A. Logo
Clinical-stage biotech developing miRNA therapeutics for inflammatory diseases.
United States of America
ABVX
ABL Diagnostics Logo
Develops molecular diagnostic solutions for managing infectious diseases.
France
ABLD
Abliva Logo
Biopharmaceutical company developing medicines for primary mitochondrial diseases.
Sweden
ABLI
AB Science Logo
Researches and develops protein kinase inhibitors for human and veterinary medicine.
France
AB
ABVC BIOPHARMA, INC. Logo
Develops botanical drugs and medical devices for oncology, ophthalmology, and CNS.
United States of America
ABVC
ACADIA PHARMACEUTICALS INC Logo
Biopharmaceutical company developing medicines for CNS disorders and rare diseases.
United States of America
ACAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.